VIA
CVAC

Vident Investment Advisory’s CureVac CVAC Stock Holding History

Vident Investment Advisory’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,452
Closed -$768K – 1172
2021
Q2 		$768K Sell
10,452
-294
-3% -$29.4K 0.02% 721
2021
Q1 		$983K Buy
+10,746
New +$1.04M 0.03% 614

Other funds holding CVAC

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Vident Investment Advisory's CVAC Position: Q3 2021 in Review

Vident Investment Advisory sold out of CureVac (CVAC) in Q3 2021, closing a stake of 10,452 shares — an estimated $768K sold.

Vident Investment Advisory first reported a position in CVAC in Q1 2021 and held it in 2 quarters. The position peaked at $983K in Q1 2021. 111 funds tracked by Wall St. Rank hold CVAC as of Q3 2021.

  • Vident Investment Advisory reported no remaining CureVac position as of Q3 2021 after selling out during the quarter.
  • Vident Investment Advisory sold 10,452 CureVac shares in Q3 2021, an estimated $768K.
  • Vident Investment Advisory first reported a position in CureVac in Q1 2021 and held it in 2 quarters.
  • Vident Investment Advisory's CureVac position peaked at $983K in Q1 2021.
  • 111 funds tracked by Wall St. Rank held CureVac as of Q3 2021.

Based on Vident Investment Advisory's 13F filing for Q3 2021, filed 12 Nov 2021.